InvestorsHub Logo
Followers 826
Posts 119467
Boards Moderated 15
Alias Born 09/05/2002

Re: jbog post# 15598

Saturday, 06/04/2016 3:36:20 PM

Saturday, June 04, 2016 3:36:20 PM

Post# of 20689
MNTA presents final Necuparanib data from phase-1 portion of phase-1/2 trial in pancreatic cancer at ASCO:

#msg-123093925

The PR rate of 56% (9/16) is higher than the 50% rate in the ASCO abstract; i.e. one additional patient had a response after the cut-off date for the abstract.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”